Clough Capital Partners L P Arvinas, Inc. Transaction History

Clough Capital Partners L P

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$36.01 - $74.24 $8.26 Million - $17 Million	-229,300 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $4.17 Million - $6.09 Million	63,300 Added 38.13%	229,300 $18.8 Million
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $1.59 Million - $2.34 Million	21,700 Added 15.04%	166,000 $13.6 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $8.72 Million - $12.2 Million	144,300 New	144,300 $11.1 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.21B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

Stay updated on Clough Capital Partners L P with notifications on news.